PharmaShots | Incisive News in 3 Shots

Subscribe Now

Myelodysplastic Syndrome

Gilead's Magrolimab Receives the US FDA's Breakthrough Therapy Designation for Myelodysplastic Syndrome

Gilead's Magrolimab Receives the US FDA's Breakthrough Therapy Designation for Myelodysplastic Syndrome

September 16, 2020

Gilead to Acquire Forty Seven for $4.9B

Gilead to Acquire Forty Seven for $4.9B

March 2, 2020

$Agios' Tibsovo (ivosidenib) Receives the US FDA's Breakthrough Therapy Designation for Patients with Relapsed or Refractory Myelodysplastic Syndrome with an IDH1 Mutation$

Agios' Tibsovo (ivosidenib) Receives the US FDA's Breakthrough Therapy Designation for Patients with Relapsed or Refractory Myelod...

December 16, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us